Digestive diseases (Basel, Switzerland) · 2025
Endoscopic Anti-Reflux Mucosal Interventions for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Efficacy, Safety, and Comparative Outcomes.
СтатьяСистематический обзорМетаанализСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Tingting, Wen Fuxing, Zhao Jiayuan, Zhang Wei
Аннотация
INTRODUCTION: This meta-analysis evaluates efficacy and safety of anti-reflux mucosal interventions (ARMIs) for gastroesophageal reflux disease (GERD), and comparative effectiveness against traditional interventions.
METHODS: A systematic search identified 37 studies (11 comparative and 26 single-arm studies) evaluating ARMIs. Outcomes included GERD symptom scores (GERD-Q, GERD-HRQL), DeMeester score, acid exposure time (AET), complete cessation of proton-pump inhibitor (PPI) therapy, and adverse events (AEs). Random-effects models pooled standardized mean differences and risk ratios (RRs). Subgroup analyses compared techniques (endoscopic mucosal resection [EMR], endoscopic submucosal dissection [ESD], anti-reflux mucosal ablation [ARMA]).
RESULTS: Technical success was 100%, with a mean procedure time of 42.09 min. ARMIs significantly reduced the proportion of patients using PPI (RR = 2.22-3.06; <3-24 months; p ≤ 0.001) and improved GERD-Q, GERD-HRQL, and DeMeester scores through 36 months (p < 0.05). AET decreased at 3-6 months (p < 0.001). Overall AEs occurred in 13% of cases (bleeding: 3%; stricture: 8%; dysphagia: 8%). Subgroup analyses demonstrated efficacy across EMR, ESD, and ARMA subtypes (p < 0.05), though AE rates differed. Compared to laparoscopic Nissen fundoplication (LNF), ARMIs showed similar symptom relief (p > 0.05), shorter procedures (p < 0.001), and lower dysphagia (X% vs. Y%; p = 0.01). Versus Stretta, ARMIs had similar PPI discontinuation rates (p = 0.258) and GERD-Q improvement (p = 0.696).
CONCLUSION: ARMIs offer durable symptom control with reduced PPI dependency. Preliminary comparative data suggest potential efficacy/safety advantages over LNF/Stretta, warranting randomized trials. Technique selection should balance efficacy and AE profiles.
METHODS: A systematic search identified 37 studies (11 comparative and 26 single-arm studies) evaluating ARMIs. Outcomes included GERD symptom scores (GERD-Q, GERD-HRQL), DeMeester score, acid exposure time (AET), complete cessation of proton-pump inhibitor (PPI) therapy, and adverse events (AEs). Random-effects models pooled standardized mean differences and risk ratios (RRs). Subgroup analyses compared techniques (endoscopic mucosal resection [EMR], endoscopic submucosal dissection [ESD], anti-reflux mucosal ablation [ARMA]).
RESULTS: Technical success was 100%, with a mean procedure time of 42.09 min. ARMIs significantly reduced the proportion of patients using PPI (RR = 2.22-3.06; <3-24 months; p ≤ 0.001) and improved GERD-Q, GERD-HRQL, and DeMeester scores through 36 months (p < 0.05). AET decreased at 3-6 months (p < 0.001). Overall AEs occurred in 13% of cases (bleeding: 3%; stricture: 8%; dysphagia: 8%). Subgroup analyses demonstrated efficacy across EMR, ESD, and ARMA subtypes (p < 0.05), though AE rates differed. Compared to laparoscopic Nissen fundoplication (LNF), ARMIs showed similar symptom relief (p > 0.05), shorter procedures (p < 0.001), and lower dysphagia (X% vs. Y%; p = 0.01). Versus Stretta, ARMIs had similar PPI discontinuation rates (p = 0.258) and GERD-Q improvement (p = 0.696).
CONCLUSION: ARMIs offer durable symptom control with reduced PPI dependency. Preliminary comparative data suggest potential efficacy/safety advantages over LNF/Stretta, warranting randomized trials. Technique selection should balance efficacy and AE profiles.